How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Alexander Kriz
Advertisement
Alexander Kriz is Director at Executive Insight.
Articles by Alexander Kriz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
3
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD
4
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
5